Table of Content

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights


2. Assumptions and Research Methodology


3. Executive Summary: Global Multiple Sclerosis Drugs Market


4. Market Overview

4.1. Introduction

4.1.1. Multiple Sclerosis Drugs Market Introduction

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Multiple Sclerosis Drugs Market Analysis and Forecast, 2017–2027

4.4.1. Market Revenue Projections (US$ Mn)


5. Key Insights

5.1. Pipeline Analysis

5.2. Regulatory Scenario

5.3. Disease Epidemiology

5.4. Market Access Overview

5.5. Key Mergers & Acquisitions


6. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Drug Class

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Market Value Forecast, by Drug Class, 2017–2027

6.3.1. Interferon Beta

6.3.2. Sphingosine 1 Phosphate Receptor Modulators

6.3.3. Mixed Polymers

6.3.4. NF-?B Inhibitor

6.3.5. Pyrimidine Synthesis Inhibitor

6.3.6. Monoclonal Antibodies

6.3.7. Corticosteroids

6.3.8. Adrenocorticotropic Hormone

6.3.9. Others

6.4. Market Attractiveness, by Drug Class


7. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Disease Type

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Market Value Forecast, by Disease Type, 2017–2027

7.3.1. Relapsing-remitting MS (RRMS)

7.3.2. Primary-progressive MS (PPMS)

7.3.3. Secondary-progressive MS (SPMS)

7.3.4. Progressive-relapsing MS (PRMS)

7.4. Market Attractiveness, by Disease Type


8. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Route of Administration

8.1. Introduction & Definition

8.2. Key Findings / Developments

8.3. Market Value Forecast, by Route of Administration, 2017–2027

8.3.1. Parenteral

8.3.2. Oral

8.4. Market Attractiveness by Route of Administration


9. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Distribution Channel

9.1. Introduction & Definition

9.2. Key Findings / Developments

9.3. Market Value Forecast, by Distribution Channel, 2017–2027

9.3.1. Hospital Pharmacies

9.3.2. Retail Pharmacies & Drug Stores

9.3.3. Online Pharmacies

9.4. Market Attractiveness, by Distribution Channel


10. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Region

10.1. Key Findings

10.2. Market Value Forecast, by Region

10.2.1. North America

10.2.2. Europe

10.2.3. Asia Pacific

10.2.4. Latin America

10.2.5. Middle East & Africa

10.3. Market Attractiveness, by Country/Region


11. North America Multiple Sclerosis Drugs Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Market Value Forecast, by Drug Class, 2017–2027

11.2.1. Interferon Beta

11.2.2. Sphingosine 1 Phosphate Receptor Modulators

11.2.3. Mixed Polymers

11.2.4. NF-?B Inhibitor

11.2.5. Pyrimidine Synthesis Inhibitor

11.2.6. Monoclonal Antibodies

11.2.7. Corticosteroids

11.2.8. Adrenocorticotropic Hormone

11.2.9. Others

11.3. Market Value Forecast, by Disease Type, 2017–2027

11.3.1. Relapsing-remitting MS (RRMS)

11.3.2. Primary-progressive MS (PPMS)

11.3.3. Secondary-progressive MS (SPMS)

11.3.4. Progressive-relapsing MS (PRMS)

11.4. Market Value Forecast, by Route of Administration, 2017–2027

11.4.1. Parenteral

11.4.2. Oral

11.5. Market Value Forecast, by Distribution Channel, 2017–2027

11.5.1. Hospital Pharmacies

11.5.2. Retail Pharmacies & Drug Stores

11.5.3. Online Pharmacies

11.6. Market Value Forecast, by Country, 2017–2027

11.6.1. U.S.

11.6.2. Canada

11.7. Market Attractiveness Analysis

11.7.1. By Drug Class

11.7.2. By Disease Type

11.7.3. By Route of Administration

11.7.4. By Distribution Channel

11.7.5. By Country


12. Europe Multiple Sclerosis Drugs Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Market Value Forecast, by Drug Class, 2017–2027

12.2.1. Interferon Beta

12.2.2. Sphingosine 1 Phosphate Receptor Modulators

12.2.3. Mixed Polymers

12.2.4. NF-?B Inhibitor

12.2.5. Pyrimidine Synthesis Inhibitor

12.2.6. Monoclonal Antibodies

12.2.7. Corticosteroids

12.2.8. Adrenocorticotropic Hormone

12.2.9. Others

12.3. Market Value Forecast, by Disease Type, 2017–2027

12.3.1. Relapsing-remitting MS (RRMS)

12.3.2. Primary-progressive MS (PPMS)

12.3.3. Secondary-progressive MS (SPMS)

12.3.4. Progressive-relapsing MS (PRMS)

12.4. Market Value Forecast, by Route of Administration, 2017–2027

12.4.1. Parenteral

12.4.2. Oral

12.5. Market Value Forecast, by Distribution Channel, 2017–2027

12.5.1. Hospital Pharmacies

12.5.2. Retail Pharmacies & Drug Stores

12.5.3. Online Pharmacies

12.6. Market Value Forecast, by Country/Sub-region, 2017–2027

12.6.1. Germany

12.6.2. U.K.

12.6.3. France

12.6.4. Italy

12.6.5. Spain

12.6.6. Rest of Europe

12.7. Market Attractiveness Analysis

12.7.1. By Drug Class

12.7.2. By Disease Type

12.7.3. By Route of Administration

12.7.4. By Distribution Channel

12.7.5. By Country/Sub-region

13. Asia Pacific Multiple Sclerosis Drugs Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Market Value Forecast, by Drug Class, 2017–2027

13.2.1. Interferon Beta

13.2.2. Sphingosine 1 Phosphate Receptor Modulators

13.2.3. Mixed Polymers

13.2.4. NF-?B Inhibitor

13.2.5. Pyrimidine Synthesis Inhibitor

13.2.6. Monoclonal Antibodies

13.2.7. Corticosteroids

13.2.8. Adrenocorticotropic Hormone

13.2.9. Others

13.3. Market Value Forecast, by Disease Type, 2017–2027

13.3.1. Relapsing-remitting MS (RRMS)

13.3.2. Primary-progressive MS (PPMS)

13.3.3. Secondary-progressive MS (SPMS)

13.3.4. Progressive-relapsing MS (PRMS)

13.4. Market Value Forecast, by Route of Administration, 2017–2027

13.4.1. Parenteral

13.4.2. Oral

13.5. Market Value Forecast, by Distribution Channel, 2017–2027

13.5.1. Hospital Pharmacies

13.5.2. Retail Pharmacies & Drug Stores

13.5.3. Online Pharmacies

13.6. Market Value Forecast, by Country/Sub-region, 2017–2027

13.6.1. China

13.6.2. India

13.6.3. Japan

13.6.4. Australia & New Zealand

13.6.5. Rest of Asia Pacific

13.7. Market Attractiveness Analysis

13.7.1. By Drug Class

13.7.2. By Disease Type

13.7.3. By Route of Administration

13.7.4. By Distribution Channel

13.7.5. By Country/Sub-region

14. Latin America Multiple Sclerosis Drugs Market Analysis and Forecast

14.1. Introduction

14.1.1. Key Findings

14.2. Market Value Forecast, by Drug Class, 2017–2027

14.2.1. Interferon Beta

14.2.2. Sphingosine 1 Phosphate Receptor Modulators

14.2.3. Mixed Polymers

14.2.4. NF-?B Inhibitor

14.2.5. Pyrimidine Synthesis Inhibitor

14.2.6. Monoclonal Antibodies

14.2.7. Corticosteroids

14.2.8. Adrenocorticotropic Hormone

14.2.9. Others

14.3. Market Value Forecast, by Disease Type, 2017–2027

14.3.1. Relapsing-remitting MS (RRMS)

14.3.2. Primary-progressive MS (PPMS)

14.3.3. Secondary-progressive MS (SPMS)

14.3.4. Progressive-relapsing MS (PRMS)

14.4. Market Value Forecast, by Route of Administration, 2017–2027

14.4.1. Parenteral

14.4.2. Oral

14.5. Market Value Forecast, by Distribution Channel, 2017–2027

14.5.1. Hospital Pharmacies

14.5.2. Retail Pharmacies & Drug Stores

14.5.3. Online Pharmacies

14.6. Market Value Forecast, by Country/Sub-region, 2017–2027

14.6.1. Brazil

14.6.2. Mexico

14.6.3. Rest of Latin America

14.7. Market Attractiveness Analysis

14.7.1. By Drug Class

14.7.2. By Disease Type

14.7.3. By Route of Administration

14.7.4. By Distribution Channel

14.7.5. By Country/Sub-region


15. Middle East & Africa Multiple Sclerosis Drugs Market Analysis and Forecast

15.1. Introduction

15.1.1. Key Findings

15.2. Market Value Forecast, by Drug Class, 2017–2027

15.2.1. Interferon Beta

15.2.2. Sphingosine 1 Phosphate Receptor Modulators

15.2.3. Mixed Polymers

15.2.4. NF-?B Inhibitor

15.2.5. Pyrimidine Synthesis Inhibitor

15.2.6. Monoclonal Antibodies

15.2.7. Corticosteroids

15.2.8. Adrenocorticotropic Hormone

15.2.9. Others

15.3. Market Value Forecast, by Disease Type, 2017–2027

15.3.1. Relapsing-remitting MS (RRMS)

15.3.2. Primary-progressive MS (PPMS)

15.3.3. Secondary-progressive MS (SPMS)

15.3.4. Progressive-relapsing MS (PRMS)

15.4. Market Value Forecast, by Route of Administration, 2017–2027

15.4.1. Parenteral

15.4.2. Oral

15.5. Market Value Forecast, by Distribution Channel, 2017–2027

15.5.1. Hospital Pharmacies

15.5.2. Retail Pharmacies & Drug Stores

15.5.3. Online Pharmacies

15.6. Market Value Forecast, by Country/Sub-region, 2017–2027

15.6.1. GCC Countries

15.6.2. South Africa

15.6.3. Rest of Middle East & Africa

15.7. Market Attractiveness Analysis

15.7.1. By Drug Class

15.7.2. By Disease Type

15.7.3. By Route of Administration

15.7.4. By Distribution Channel

15.7.5. By Country/Sub-region


16. Competition Landscape

16.1. Market Share Analysis, by Company, 2018

16.2. Company Profiles

16.2.1. Bayer AG

16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

16.2.1.2. Financial Overview

16.2.1.3. Product Portfolio

16.2.1.4. SWOT Analysis

16.2.1.5. Strategic

16.2.2. Teva Pharmaceutical Industries Ltd.

16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

16.2.2.2. Financial Overview

16.2.2.3. Product Portfolio

16.2.2.4. SWOT Analysis

16.2.2.5. Strategic

16.2.3. Novartis AG

16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

16.2.3.2. Financial Overview

16.2.3.3. Product Portfolio

16.2.3.4. SWOT Analysis

16.2.3.5. Strategic

16.2.4. Sanofi

16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

16.2.4.2. Financial Overview

16.2.4.3. Product Portfolio

16.2.4.4. SWOT Analysis

16.2.4.5. Strategic

16.2.5. F. Hoffmann-La Roche Ltd.

16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

16.2.5.2. Financial Overview

16.2.5.3. Product Portfolio

16.2.5.4. SWOT Analysis

16.2.5.5. Strategic

16.2.6. Celgene Corporation

16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

16.2.6.2. Financial Overview

16.2.6.3. Product Portfolio

16.2.6.4. SWOT Analysis

16.2.6.5. Strategic

16.2.7. Acorda Therapeutics, Inc.

16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

16.2.7.2. Financial Overview

16.2.7.3. Product Portfolio

16.2.7.4. SWOT Analysis

16.2.7.5. Strategic

16.2.8. Biogen, Inc.

16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

16.2.8.2. Financial Overview

16.2.8.3. Product Portfolio

16.2.8.4. SWOT Analysis

16.2.8.5. Strategic

16.2.9. Actelion Pharmaceuticals (Johnson & Johnson)

16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

16.2.9.2. Financial Overview

16.2.9.3. Product Portfolio

16.2.9.4. SWOT Analysis

16.2.9.5. Strategic

16.2.10. EMD Serono (Merck KGaA)

16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

16.2.10.2. Financial Overview

16.2.10.3. Product Portfolio

16.2.10.4. SWOT Analysis

16.2.10.5. Strategic

16.2.11. AbbVie, Inc.

16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

16.2.11.2. Financial Overview

16.2.11.3. Product Portfolio

16.2.11.4. SWOT Analysis

16.2.11.5. Strategic



List of Figures



Figure 01: Global Multiple Sclerosis Drugs Market Snapshot

Figure 02: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, 2017–2027

Figure 03: Global Multiple Sclerosis Drugs Market Value Share, by Drug Class, 2018

Figure 04: Global Multiple Sclerosis Drugs Market Value Share, by Disease Type, 2018

Figure 05: Global Multiple Sclerosis Drugs Market Value Share, by Route of Administration, 2018

Figure 06: Global Multiple Sclerosis Drugs Market Value Share, by Distribution Channel, 2018

Figure 07: Global Multiple Sclerosis Drugs Market Value Share, by Region, 2018

Figure 08: Regulatory Approval Process - U.S.

Figure 09: Regulatory Approval Process - Europe

Figure 10: Regulatory Approval Process - Japan

Figure 11: Regulatory Approval Process - China

Figure 12: Global Multiple Sclerosis Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 13: Global Multiple Sclerosis Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 14: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Interferon Beta, 2017–2027

Figure 15: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Sphingosine 1 Phosphate Receptor Modulators, 2017–2027

Figure 16: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Mixed Polymers, 2017–2027

Figure 17: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by NF-?B Inhibitors, 2017–2027

Figure 18: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Pyrimidine Synthesis Inhibitors, 2017–2027

Figure 19: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Monoclonal Antibodies, 2017–2027

Figure 20: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Corticosteroids, 2017–2027

Figure 21: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Adrenocorticotropic Hormone, 2017–2027

Figure 22: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2017–2027

Figure 23: Global Multiple Sclerosis Drugs Market Value Share Analysis, by Disease Type, 2018 and 2027

Figure 24: Global Multiple Sclerosis Drugs Market Attractiveness Analysis, by Disease Type, 2019–2027

Figure 25: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Relapsing-remitting MS (RRMS), 2017–2027

Figure 26: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Primary-progressive MS (PPMS), 2017–2027

Figure 27: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Secondary-progressive MS (SPMS), 2017–2027

Figure 28: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Progressive-relapsing MS (PRMS), 2017–2027

Figure 29: Global Multiple Sclerosis Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 30: Global Multiple Sclerosis Drugs Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 31: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Parenteral, 2017–2027

Figure 32: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Oral, 2017–2027

Figure 33: Global Multiple Sclerosis Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 34: Global Multiple Sclerosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 35: Global Multiple Sclerosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027

Figure 36: Global Multiple Sclerosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacies & Drug Stores, 2017–2027

Figure 37: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacies, 2017–2027

Figure 38: Global Multiple Sclerosis Drugs Market Value Share, by Region, 2018 and 2027

Figure 39: Global Multiple Sclerosis Drugs Market Attractiveness, by Region, 2019–2027

Figure 40: North America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 41: North America Multiple Sclerosis Drugs Market Value Share (%) Analysis, by Country, 2018 & 2027

Figure 42: North America Multiple Sclerosis Drugs Market Attractiveness Analysis, by Country, 2019?2027

Figure 43: North America Multiple Sclerosis Drugs Market Value Share (%) Analysis, by Drug Class, 2018 & 2027

Figure 44: North America Multiple Sclerosis Drugs Market Attractiveness, by Drug Class, 2019?2027

Figure 45: North America Multiple Sclerosis Drugs Market Value Share (%) Analysis, by Disease Type, 2018 & 2027

Figure 46: North America Multiple Sclerosis Drugs Market Attractiveness, by Disease Type, 2019?2027

Figure 47: North America Multiple Sclerosis Drugs Market Value Share (%) Analysis, by Route of Administration, 2018 & 2027

Figure 48: North America Multiple Sclerosis Drugs Market Value Share (%) Analysis, by Distribution Channel, 2018 & 2027

Figure 49: North America Multiple Sclerosis Drugs Market Attractiveness, by Route of Administration, 2019?2027

Figure 50: North America Multiple Sclerosis Drugs Market Attractiveness, by Distribution Channel, 2019?2027

Figure 51: Europe Multiple Sclerosis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 52: Europe Multiple Sclerosis Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 53: Europe Multiple Sclerosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019?2027

Figure 54: Europe Multiple Sclerosis Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 55: Europe Multiple Sclerosis Drugs Market Attractiveness Analysis, by Drug Class, 2019?2027

Figure 56: Europe Multiple Sclerosis Drugs Market Value Share (%) Analysis, by Disease Type, 2018 & 2027

Figure 57: Europe Multiple Sclerosis Drugs Market Attractiveness, by Disease Type, 2019?2027

Figure 58: Europe Multiple Sclerosis Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 59: Europe Multiple Sclerosis Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 60: Europe Multiple Sclerosis Drugs Market Attractiveness Analysis, by Route of Administration, 2019?2027

Figure 61: Europe Multiple Sclerosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2019?2027

Figure 62: Asia Pacific Multiple Sclerosis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 63: Asia Pacific Multiple Sclerosis Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 64: Asia Pacific Multiple Sclerosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 65: Asia Pacific Multiple Sclerosis Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 66: Asia Pacific Multiple Sclerosis Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 67: Asia Pacific Multiple Sclerosis Drugs Market Value Share (%) Analysis, by Disease Type, 2018 & 2027

Figure 68: Asia Pacific Multiple Sclerosis Drugs Market Attractiveness, by Disease Type, 2019?2027

Figure 69: Asia Pacific Multiple Sclerosis Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 70: Asia Pacific Multiple Sclerosis Drugs Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 71: Asia Pacific Multiple Sclerosis Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 72: Asia Pacific Multiple Sclerosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 73: Latin America Multiple Sclerosis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 74: Latin America Multiple Sclerosis Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 75: Latin America Multiple Sclerosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 76: Latin America Multiple Sclerosis Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 77: Latin America Multiple Sclerosis Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 78: Latin America Multiple Sclerosis Drugs Market Value Share (%) Analysis, by Disease Type, 2018 and 2027

Figure 79: Latin America Multiple Sclerosis Drugs Market Attractiveness, by Disease Type, 2019?2027

Figure 80: Latin America Multiple Sclerosis Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 81: Latin America Multiple Sclerosis Drugs Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 82: Latin America Multiple Sclerosis Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 83: Latin America Multiple Sclerosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 84: Middle East & Africa Multiple Sclerosis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 85: Middle East & Africa Multiple Sclerosis Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 86: Middle East & Africa Multiple Sclerosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019-2027

Figure 87: Middle East & Africa Multiple Sclerosis Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 88: Middle East & Africa Multiple Sclerosis Drugs Market Attractiveness Analysis, by Drug Class, 2019-2027

Figure 89: Middle East & Africa Multiple Sclerosis Drugs Market Value Share (%) Analysis, by Disease Type, 2018 & 2027

Figure 90: Middle East & Africa Multiple Sclerosis Drugs Market Attractiveness, by Disease Type, 2019?2027

Figure 91: Middle East & Africa Multiple Sclerosis Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 92: Middle East & Africa Multiple Sclerosis Drugs Market Attractiveness Analysis, by Route of Administration, 2019-2027

Figure 93: Middle East & Africa Multiple Sclerosis Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 94: Middle East & Africa Multiple Sclerosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2019-2027

 

List of Tables



Table 01: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 02: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

Table 03: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 04: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 05: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 06: North America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 07: North America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 08: North America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

Table 09: North America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 10: North America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 11: Europe Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 12: Europe Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 13: Europe Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

Table 14: Europe Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 15: Europe Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 16: Asia Pacific Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 17: Asia Pacific Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 18: Asia Pacific Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

Table 19: Asia Pacific Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 20: Asia Pacific Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 21: Latin America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 22: Latin America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 23: Latin America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

Table 24: Latin America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 25: Latin America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 26: Middle East & Africa Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 27: Middle East & Africa Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 28: Middle East & Africa Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

Table 29: Middle East & Africa Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 30: Middle East & Africa Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027